Back to search results

Precision Treatment for Smoking Cessation in Oncology Patients

This study is looking at two ways to help oncology patients quit smoking: usual care and a special "precision treatment." Usual care follows standard guidelines for helping people quit. The precision treatment also uses standard guidelines but adds personalized recommendations based on your clinical information, genetic makeup, and other health markers. Researchers want to see if this precision treatment helps more patients receive tobacco treatment medication, use these medications, and successfully quit smoking after 6 months. The study aims to enroll 132 participants aged 18 to 89 who currently smoke at least 5 cigarettes a day and can speak English. The current recruitment status is unclear.

Study design
This is an interventional study comparing usual care to precision treatment. It plans to enroll 132 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your smoking abstinence and use of cessation medication will be measured 6 months after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07166120

Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients

Recruiting
NAAges 18–89InterventionalPrevention
Washington University School of Medicine
~132 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:Usual carePrecision treatment

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient receipt of tobacco treatment medication for smoking cessation
Measured over 6 months post-intervention
+2 more outcomes measured

Conditions

Smoking Cessation
Smoking
Physician's Role

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT07166120

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • John Cochran Veteran's Affairs Medical Center

    St Louis, Missouristudy coordinator listed

    Recruiting

  • Washington University School of Medicine

    St Louis, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Li-Shiun Chen, ScD, M.D., MPH · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Li-Shiun Chen, ScD, M.D., MPH
[email protected]
314-362-3932
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient at participating clinic
Age 18-89 years
Current smoking (average cigarettes per day ≥5)
Can speak and understand English
Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion

Active use of smoking cessation medication (within the past 30 days)
Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)
Patients who were deemed by the investigator to be ineligible for participation in the trial

What this trial measures

  • Patient receipt of tobacco treatment medication for smoking cessation6 months post-intervention

    This will be quantified by the proportion of enrolled patients who receive cessation medication.

  • Patient use of cessation medication6 months post-intervention

    This will be quantified by the proportion of patients taking any cessation medication from time of enrollment through 6 months post-intervention.

  • Patient smoking abstinence6 months post-intervention

    This will be quantified by the proportion of patients who smoke with bioverified point-prevalent abstinence at 6 months.